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AbstrACt
Introduction The optimal diagnostic imaging strategy for 
fracture-related infection (FRI) remains to be established. 
In this prospective study, the three commonly used 
advanced imaging techniques for diagnosing FRI will 
be compared. Primary endpoints are (1) determining 
the overall diagnostic performances of white blood cell 
(WBC) scintigraphy, fluorodeoxyglucose positron emission 
tomography (FDG-PET) and magnetic resonance imaging 
(MRI) in patients with suspected FRI and (2) establishing 
the most accurate imaging strategy for diagnosing FRI.
Methods and analysis This study is a non-randomised, 
partially blinded, prospective cohort study involving 
two level 1 trauma centres in The Netherlands. All adult 
patients who require advanced medical imaging for 
suspected FRI are eligible for inclusion. Patients will 
undergo all three investigational imaging procedures (WBC 
scintigraphy, FDG-PET and MRI) within a time frame of 14 
days after inclusion. The reference standard will be the 
result of at least five intraoperative sampled microbiology 
cultures, or, in case of no surgery, the clinical presence 
or absence of infection at 1 year follow-up. Initially, the 
results of all three imaging modalities will be available 
to the treating team as per local protocol. At a later time 
point, all scans will be centrally reassessed by nuclear 
medicine physicians and radiologists who are blinded for 
the identity of the patients and their clinical outcome. The 
discriminative ability of the imaging modalities will be 
quantified by several measures of diagnostic accuracy.
Ethics and dissemination Approval of the study by 
the Institutional Review Board has been obtained prior 
to the start of this study. The results of this trial will be 
disseminated by publication of peer-reviewed manuscripts, 
presentation in abstract form at scientific meetings and 
data sharing with other investigators through academically 
established means.
trial registration number The IFI trial is registered in the 
Netherlands Trial Register (NTR7490).
IntroduCtIon
Fracture-related infection (FRI)1 is one of the 
most severe and challenging complications in 
trauma surgery. As with most medical condi-
tions, the key for a successful treatment of FRI 
is a prompt and accurate diagnosis. Partic-
ularly a low-grade FRI, with an often closed 
wound and little or no physical inflammatory 
signs, is not easy to recognise.
On average, the incidence of FRI is 
1%–5%2 3 with outliers up to 45% in case of 
very severe tissue damage and/or contam-
inated wounds.4 5 The exact number of all 
fractures that need surgical stabilisation is 
unknown but it is reported that roughly 
one-third of all patients with a fracture need 
hospitalisation and that 80% of these admitted 
patients need surgical fracture care.6 7 The 
incidence of fractures in men is 11.67/1000/
year and in women 10.65/1000/year.8 This 
implies that in The Netherlands (the Dutch 
population in 2018 was roughly 17.2 million) 
approximately 3000 patients are diagnosed 
with FRI every year. The number of suspected 
FRIs is undoubtedly much higher and many 
strengths and limitations of this study
 ► This study is the first to prospectively examine the 
accuracy of the advanced medical imaging tech-
niques such as white blood cell scintigraphy, fluo-
rodeoxyglucose positron emission tomography and 
MRI for diagnosing fracture-related infection (FRI).
 ► The cohort design allows for performing all three 
investigational imaging modalities in each includ-
ed patient which will result in a large comparable 
dataset.
 ► The multicenter nature of the study will increase ex-
ternal validity of the findings.
 ► The clinical assessment of the presence of FRI 
during follow-up could be prone to inaccuracies due 
to the subjective nature of clinical judgement.
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age ≥18 years Age <18 years
Suspected FRI according 
to the suggestive criteria 




Inability to comply with 
study protocol (eg, due to 
claustrophobia)
  Inability to comply with follow-
up (eg, due to language barrier 
or expected loss to follow-up 
≤1 year)
  Known allergies for intravenous 
contrast or any of the used 
nuclear tracers
  No need for advanced imaging 
techniques, for example, in case 
of early (within 30 days) surgical 
site infection
Pregnant or lactating woman
Uncontrolled diabetes mellitus 
type 1 or 2
FRI, fracture-related infection.
of these patients require some form of additional diag-
nostic imaging to confirm or rule out this diagnosis.
FRIs may seem similar to other orthopaedic infections 
(such as prosthetic joint infections, infected diabetic feet 
and spondylodiscitis) but there are distinct discrepan-
cies. One of them is that the treatment goal is different: 
stable fixation and ultimately consolidation of the frac-
ture with the option of implant removal and not, for 
example, an absolute need for retaining the arthro-
plasty. Similar differences apply for diagnostic imaging. 
Regenerating bone and soft tissue healing after surgery 
and trauma may influence imaging quality and mimic 
infection. Commonly requested imaging modalities in 
orthopaedic trauma surgery are conventional X-ray and 
plain computed tomography (CT). These techniques are 
particularly good in establishing the degree of fracture 
healing and the position and integrity of the implants but 
their accuracy for diagnosing FRI is low. More advanced 
imaging techniques, such as magnetic resonance imaging 
(MRI), fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) or white blood cell (WBC) scintig-
raphy are being used to actually diagnose FRI. In the last 
decade, the use of hybrid camera systems (single photon 
emission computed tomography (SPECT)-CT, PET-CT or 
PET-MRI) led to increased precision of the localisation of 
the infection and, as a consequence, to higher diagnostic 
accuracy rates.9–11
At this moment, no prospective sufficiently powered 
study has been published on the diagnostic accuracy of 
medical imaging modalities for FRI.9 10 The European 
Association of Nuclear Medicine (EANM), endorsed by 
the European Bone and Joint Infection Society (EBJIS), 
developed guidelines in which the WBC scintigraphy 
with SPECT/CT is regarded to be the most accurate 
advanced imaging technique for peripheral bone infec-
tion in patients with recent fractures or hardware in 
situ.12 However, this recommendation is based on scarce 
evidence in the literature and diagnostic studies specifi-
cally focussing on FRI are limited and report conflicting 
outcomes.10 13 As a result, there are no evidence-based 
diagnostic guidelines or protocols and a variety of diag-
nostic strategies depending on local availability and local 
preference of imaging techniques are being used.14 15 
These random strategies can lead to unnecessary imaging 
requests and therefore unnecessary delay of treatment 
and excessive medical costs.
To resolve this omission, we designed The Accuracy 
of Diagnostic Imaging Techniques in Patients with a 
Suspected Fracture-related Infection (IFI) Trial.
Primary endpoints
1. Determining the overall diagnostic performances of 
WBC scintigraphy + SPECT/CT, FDG-PET/CT and MRI 
in patients with suspected FRIs.
secondary endpoints
1. Determining whether the accuracy of the different 
imaging modalities is influenced by patient-related 
factors such as in situ implants (plates, screws and in-
tramedullary nails), recent surgery, open wounds, con-
comitant antibiotic treatment or comorbidities.
2. Determining which imaging modality provides the 
most valuable information to the surgeon for planning 
revision surgery, such as the exact location of the in-
fection, the extent of the infection or the presence of 
sequestra, cloacae, sinus tracts, intracortical or soft tis-
sue abscesses.
3. To assess the quality of life and physical performance 
of patients with suspected FRIs by using validated pa-
tient-reported outcome measures.
4. To design an evidence-based, feasible and cost-effective 
diagnostic pathway for patients with suspected FRIs.
MEthods And AnAlysIs
study design
This study is a non-randomised, partially blinded, 
prospective cohort study involving two level 1 trauma 
centres in The Netherlands: The University Medical 
Centre Groningen (UMCG) and the University Medical 
Centre Utrecht (UMCU). The UMCG is the leading and 
coordinating centre of this study.
Patient population
The inclusion and exclusion criteria are presented in 
table 1. Patients will be recruited at the trauma surgical or 
orthopaedic outpatient departments, clinical wards and/
or the emergency department of the participating hospi-
tals. All consecutive adult patients in the participating 
centres, who require advanced medical imaging for 
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box 1 suggestive and confirmatory fracture-related 
infection Consensus definition criteria.1
a. Confirmatory criteria
 ► Presence of a fistula, sinus or wound breakdown (with communica-
tion to the bone or implant).
 ► Phenotypically indistinguishable pathogens identified by culture 
from at least two separate deep tissue/implant (including sonica-
tion-fluid) specimens taken during an operative intervention.
 ► Presence of microorganisms in deep tissue taken during an oper-
ative intervention, as confirmed by histopathological examination 
using specific staining techniques for bacteria or fungi.
b. Suggestive criteria
 ► Clinical signs, any one of:
 – Pain (without weight bearing, increasing over time, new onset).
 – Local redness.
 – Local swelling.
 – Increased local temperature.
 – New onset of joint effusion.
 – Fever (single oral temperature measurement of ≥38.3°C (101°F)).
 ► Radiological signs, any one of:
 – Bone lysis (at the fracture site, around the implant).
 – Implant loosening.
 – Sequestration (occurring over time).
 – Failure of progression of bone healing (ie, non-union).
 – Presence of periosteal bone formation (eg, at localisations other 
than the fracture site or in case of a consolidated fracture).
 ► Elevated serum inflammatory markers in case of a secondary rise 
(after an initial decrease) or a consistent elevation over a period in 
time, and after exclusion of other infectious foci or inflammatory 
processes:
 – Erythrocyte sedimentation rate.
 – White blood cell count.
 – C reactive protein.
 ► Persistent, increasing or new-onset wound drainage, beyond the 
first few days postoperatively, without solid alternative explanation.
 ► A pathogenic organism identified by culture from a single deep tis-
sue/implant (including sonication fluid) specimen taken during an 
operative intervention.
Figure 1 Flowchart of IFI trial. FDG-PET, 
fluorodeoxyglucose positron emission tomography; FRI, 
fracture-related infection; MRI, magnetic resonance imaging; 
IFI, imaging fracture-related infection; WBC, white blood cell.
suspected FRI are eligible for inclusion. Suspected FRI is 
defined following the clinical suggestive criteria according 
to the FRI Consensus Definition.1 These criteria are based 
on medical history and clinical examination. Patients with 
clear signs of acute postoperative surgical site infections 
within 30 days after their surgery16 will be excluded as 
they usually do not require advanced diagnostic imaging. 
The suggestive and confirmative FRI Consensus Defini-
tion criteria are provided in box 1.
Interventions
After enrolment and informed consent, patients are 
scheduled for undergoing all three investigational 
imaging procedures (WBC scintigraphy + SPECT/CT, 
FDG-PET/CT and MRI) within a time frame of 14 days 
after inclusion (figure 1).
Patient clinical management and follow-up
Next to the imaging performed, patients will be treated 
according to the local standard of care. This includes 
any additional diagnostic tests, operative treatment, 
postoperative regimen and postoperative administration 
of any medication including antibiotics, which will be 
completely left to the judgement of the treating medical 
team. The same applies to the decision whether or not to 
operate based on clinical assessment and imaging. The 
treating surgeon will be aware of the results of all regular 
and research imaging procedures performed in this study 
prior to the decision making moment whether to operate 
or not.
Included patients who are operated on the clinical 
suspicion of an FRI will all have adequate tissue sampling 
for medical microbiology (MMB) examination. Details on 
the sampling and culturing techniques are discussed in 
the Reference standard section. The presence or absence 
of FRI for this group will be judged based on the outcome 
of the MMB results. To ensure that infection-positive, 
culture-negative patients are included in the correct final 
diagnostic group, all included patients will be subjected 
to the same follow-up regime.
All patients will stay in follow-up for a minimum of 1 year 
and their clinical status will be assessed by an orthopaedic 
or trauma surgeon at 3, 6 and 12 months (assessments 
regarding diagnostic criteria for FRI at follow-up are 
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Figure 2 Study assessments IFI trial by time point. CRP, C 
reactive protein; CT, computed tomography; ESR, erythrocyte 
sedimentation rate; FDG-PET, fluorodeoxyglucose positron 
emission tomography; IFI, imaging fracture-related infection; 
iMTA, Institute of Medical Technology assessment; LC, 
leucocyte count; MCQ, medical consumption questionnaire; 
PCQ, productivity cost questionnaire; PROM, patient-
reported outcome measure; SPECT, single photon emission 
computed tomography; WBC, white blood cell.
discussed in the Reference standard section). Standard 
serum inflammation markers (C reactive protein (CRP), 
leucocyte count (LC) and erythrocyte sedimentation rate 
(ESR)) will be obtained at the time of recruitment and at 
follow-up (3, 6 and 12 months). When the patient visits 
the outpatient clinic, he/she will be asked to fill out vali-
dated patient-reported outcome questionnaires regarding 
quality of life and physical performance (EuroQol (EQ)-
5D, Short Musculoskeletal Function Assesment (SMFA)). 
Health-related productivity losses of paid and unpaid 
work will be quantified by purchasing relevant parts of the 
institute of Medical Technology Assessment Productivity 
Cost Questionnaire (iMTA PCQ).17 18 The iMTA Medical 
Consumption Questionnaire (MCQ) questionnaire and 
the the Dutch Manual for Costing studies in healthcare 
will be used to calculate the costs of medical consumption 
during the research period.19–22 The different time points 
are summarised in figure 2.
Assessment of interventional imaging
Initially, all imaging is reported on as usual in the partic-
ipating centres . The written reports will be made avail-
able through normal routine procedures and available 
for the treating physician in the electronic medical 
patient systems. At a later time point, two board-certified 
nuclear medicine physicians (for WBC scintigraphy and 
FDG-PET/CT) and two board-certified radiologists (for 
MRI), all participating in this trial, will centrally reas-
sess all scans. This is done to obtain uniformity when 
interpreting the results. Imaging interpretation criteria 
are provided in the online supplemental material.
All scans will be encoded so that the central reviewers 
will be blinded for the identity of the patient and their 
clinical outcome. Case report forms (CRF) are devel-
oped to score each scan technique. If the two observers 
disagree, a third reader will review the images and the 
final classification will be made in consensus. The scans 
will finally be classified as ‘negative for FRI’ or ‘positive 
for FRI’. The reports will also focus on specific anatomic 
features such as the presence of fistulas, sequesters and 
soft tissue involvement/abscesses. In case of surgery, 
surgeons are requested to fill out a CRF on the operative 
findings to match these with the anatomic features of the 
preoperative scans.
Imaging protocols
Preparation, administration, acquisition and inter-
pretation of all imaging techniques will be performed 
according to the existing guidelines of the EANM23 24 and 
the American College of Radiology25; details are provided 
in the online supplementary material.
reference standard
The reference standard for determining the diagnostic 
accuracy of the WBC scintigraphy, the FDG-PET/CT 
and MRI will be the presence of FRI according to the 
FRI Consensus Definition 1. For the patients who are not 
operated, the reference standard will be the presence 
of FRI during follow-up. For this purpose, a board-certi-
fied trauma or orthopaedic surgeon will record all clin-
ical findings (based on the consensus definition criteria, 
box 1 (a and b)) at 3, 6 and 12 months follow-up on a 
predesigned Case Report Form (CRF). The clinical pres-
ence or absence of infection will subsequently be judged 
according to the information provided on the CRF and 
based on the FRI Consensus Definition by two blinded 
reviewers who are not involved in the actual care of the 
patient. In all patients who are operated on at least five 
surgical bone, implant and/or tissue samples will be 
obtained for microbiology culturing. These cultures will 
be sampled in a protocolled manner with clean surgical 
instruments for each sample to avoid cross contamina-
tion.26 Preferably all antibiotics are discontinued for at 
least 2 weeks and antibiotic prophylaxis is withheld until 
the last sample is obtained.27 28 The criteria for a positive 
result based on operatively obtained cultures are listed in 
box 1 (a). To ensure that infection-positive, culture-neg-
ative patients are included in the correct final diagnostic 
group, all patients will be subjected to the same follow-up 
regime. In case of (revision) surgery during follow-up the 
same sampling protocol will be followed. Intermittent 
suggestive symptoms such as local pain or redness (with 
or without ‘treatment’ with antibiotics) alone are not 
regarded confirmative for FRI. They can however prompt 
the surgeon to order diagnostic tests followed by an oper-
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Collection of additional medical data
For all patients, information concerning patient char-
acteristics (age, gender, body mass index), social and 
working context (T=0; validated quality of life, functional 
outcome and healthcare cost questionnaires), medication 
(non steroid anti-inflammatory drugs (NSAID’s), immu-
nosuppressive drugs, antibiotics, painkillers), nicotine/
substance abuse, comorbidities (eg, diabetes), history 
of trauma/fracture, type of implants being used (plates, 
screws and intramedullary nails) in previous operations, 
clinical presentation of FRI according to the criteria of 
the consensus definition,1 laboratory results (ESR, LC, 
CRP), X-ray findings (fracture union, implant failure), 
annotation of the indication for which the physician 
prompted additional imaging, patient’s opinion about 
the preference and tolerance regarding each imaging 
modality, operation records (type, osteosynthesis insitu, 
macroscopic signs of infection according to the Cier-
ny-Mader and B.A.C.H. classification,29 30 abscess, seques-
trum, involucrum, cloacae, sinus tract, fistula or septic 
artritis according to a standardised CRF), microbiology 
results (number of deep tissue cultures, pathogens), anti-
biotic treatment and follow-up data at 3, 6 and 12 months 
(concerning clinical findings based on the consensus 
definition criteria together with validated quality of life, 
functional outcome and healthcare cost questionnaires) 
will be recorded.
Establishing a diagnostic pathway for patients with suspected 
FrI
Based on the results of this trial, a diagnostic pathway for 
patients with suspected FRI will be established. In this 
pathway, the use of the imaging modality or a combi-
nation of different imaging modalities with the highest 
accuracy and feasibility will be described. The costs of the 
different imaging modalities will be taken into account. 
For these costs, standard unit prices and rates that are 
included in the Manual for Cost Analyses, Methods and 
Standard Prices for Economic Evaluation in Health Care 
will be used.20
sample size and power
Recently, we performed a systematic review about the 
accuracy of diagnostic imaging modalities for peripheral 
post-traumatic osteomyelitis (the old terminology for 
FRI).10 Based on the best available evidence over the last 
16 years, the sensitivity for WBC scintigraphy ranged from 
50% to 100%, and specificity ranged from 40% to 97%. 
For FDG-PET, this was 83%–100% and 51%– 100%, and 
for MRI 82%–100% and 43%–60%, respectively. More-
over, studies which combined the WBC scintigraphy with 
SPECT/CT or the FDG-PET with a CT scan showed some 
increase in diagnostic accuracy measures. Overall, our 
review demonstrated that sensitivity and specificity vary 
widely between studies, because the literature about FRIs 
is limited and hampered by small case series, heteroge-
neous patient populations, different imaging acquisi-
tion and interpretations protocols and quickly evolving 
(combined) imaging techniques. Another recent publi-
cation from our group has shown that the sensitivity and 
specificity of WBC scintigraphy to diagnose FRI in a large 
retrospectively analysed patient cohort is 0.86 and 0.98, 
respectively.31 In two other recent retrospective studies on 
the accuracy of FDG-PET/CT sensitivities and specificities 
between 0.65 and 0.89 and 0.77 and 0.80 are reported, 
respectively.32 33 Based on these results we expect a differ-
ence of at least 15% in sensitivity and specificity between 
the WBC scintigraphy and the FDG-PET/CT. The accu-
racy of MRI for FRI is reported to be even lower than that 
of the FDG-PET/CT10 so this expected difference will also 
apply for this modality.
Sensitivity refers to the percentage of patients who are 
correctly identified as having the disease, in this case an 
FRI. With a sample size of n=50 (patients who actually 
have an FRI) it is possible to detect a statistically significant 
difference between the sensitivity of WBC scintigraphy 
(sensitivity of 0.86) and the other diagnostic modalities 
(maximal expected sensitivity of 0.71): 95% CI around 
the sensitivity of 0.71 will be 0.58 to 0.84. Since the sensi-
tivity of WBC scintigraphy of 0.86 is outside this 95% CI, 
it should be considered statistically significant relative to 
the sensitivity of the other diagnostic modalities.
Specificity refers to the percentage of patients who 
are correctly identified as not having the disease, in this 
case an FRI. With a sample size of n=120 (patients who 
do not have an FRI) it is possible to detect a statistically 
significant difference between the specificity of WBC 
scintigraphy (specificity of 0.98) and the other diagnostic 
modalities (maximal expected specificity of 0.83); 95% CI 
around the specificity of 0.83 will be 0.75 to 0.91. Since 
the specificity of WBC scintigraphy of 0.98 is outside this 
95% CI, it is statistically significant different relative to the 
specificity of the other diagnostic modalities.
In the aforementioned study on the accuracy of WBC 
scintigraphy for diagnosing FRI,31 it was established that 
approximately 30% of the patients who undergo diag-
nostic imaging for suspected FRI actually have an FRI. The 
study sample thus needs to contain 170 patients, of whom 
50 patients are expected to have an FRI (needed for the 
sensitivity calculation), and 120 patients are expected to 
not have an FRI (needed for the specificity calculation). 
To correct for loss-to-follow-up of approximately 20%, a 
total sample size of n=200 is needed.
Feasibility
We anticipate that we will be able to recruit a suffi-
cient number of patients during the study period. Both 
contributing hospitals in this multicentre cohort study 
are level 1 trauma centres with 50–75 patients suffering 
from FRI each year. We assume that at least half of the 
eligible patients are willing to participate in this study. 
This assumption is based on our experience that most 
trauma patients are eager to comply with additional diag-
nostic imaging in case of a suspected FRI. This could 
be due to the fact that they suffer from a long-standing 
disease and might feel underdiagnosed. Therefore, we 
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anticipate including 50–60 patients a year in this study. 
This combined with a follow-up period of 1 year will make 
it feasible to complete this study in 5 years.
statistical analysis
Summary statistics and analyses will be provided for all 
patients who undergo WBC scintigraphy + SPECT/CT, 
FDG-PET/CT and MRI. The discriminative ability of the 
imaging modalities will be quantified by several measures 
of diagnostic accuracy: sensitivity/specificity (including 
receiver operating characteristics (ROC) curves), posi-
tive and negative predictive values, positive and negative 
likelihood ratios, and the diagnostic odds ratio (OR). 
To assess whether a variable (such as type of implants, 
recent surgery, open wounds, NSAID use or concomitant 
antibiotic treatment) is predictive of a false imaging test 
result (false-positive or false-negative vs true-positive or 
true-negative), multivariable logistic regression analysis 
will be performed.
Patient and public involvement
No patients were involved in the design of this study. This 
decision was based on the fact that in a previous patient 
participating meeting for the Dutch guideline ‘diag-
nosis and treatment of FRI’ in which two authors (GG, 
AWJMG) of the current study were involved, no concerns 
regarding medical imaging were reported by any of the 
patients. However, patient-reported outcome question-
naires regarding quality of life and physical performance 
(EQ-5D, SMFA) will be part of the data collected in this 
study.
trIAl stAtus
The IFI trial has been open for recruitment since July 
2019 in the UMCG, the UMCU will follow by the end of 
this year. To date five patients have been included. Esti-
mated study duration is 60 months with a completion 
date in July 2024.
The IFI Trial is registered in the Netherlands Trial 
Register (NTR7490). Registration date: 16-09-2018. 
Website: www. trialregister. nl
EthICs And dIssEMInAtIon
Patient safety
Use of radiopharmaceuticals means exposure to ionising 
radiation. Because of the potential hazards of radia-
tion, guidelines for the exposure of healthy volunteers 
and patients in The Netherlands are specified in Besluit 
Stralingsbescherming (BS 2000), artikel 60, Staatsblad 
2001, 397 according to the guidelines of the Interna-
tional Commission on Radiological Protection. The extra 
imaging modality (depending on site specific common 
practice in collaborating centres) will be the MRI and 
either the WBC scintigraphy or the FDG-PET/CT. 
Overall, the additional radiation exposure for a patient 
participating in this trial will be 4.0 mSv. This complies 
with ICRP 62, category IIb, which means it is justified in 
patients.
data and safety monitoring board (dsMb) and interim 
analysis
All research modalities are well-established, common and 
safe procedures used in clinical practice for this patient 
population every day. Therefore, the risk of additional 
adverse events will be minimal. This means that there will 
be no need to implement a DSMB or interim analysis.
dissemination plan
The results of this trial will be disseminated by publication 
of peer-reviewed manuscripts, presentation in abstract 
form at scientific meetings and data sharing with other 
investigators through academically established means. 
The outcome of this trial will also be utilised to design 
an evidence-based, feasible and cost-effective diagnostic 
pathway for patients with suspected FRI and implement 
this in national and international guidelines.
data storage and management
All data will be entered by site principal investigators (PIs) 
or research assistants and data accuracy will be verified by 
the study PI. Data quality control measures will include 
queries to identify missing data, outliers and discrepan-
cies. Only research assistants and site PIs will have access 
to protected health information. After enrolment, a 
unique identifier will be assigned to each study subject. 
The data from all sites will be uploaded and stored using 
a web-based data management application. All computers 
will be password protected and encrypted per university 
policy. The PI will ensure that the anonymity is main-
tained. Patients will not be identified by name in any 
reports on this study. The study PI will have access to the 
final study dataset.
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